ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,661 to 1,680 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of All Cause Mortality144 of 2,596

148 of 2,602

-0.1 points

-1.4 to 1.1

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer12 of 2,596

11 of 2,602

0.0 points

-0.3 to 0.4

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of Major Adverse Cardiac Event (MACE): Number and Percentage of Participants With an Event182 of 2,596

190 of 2,602

-0.3 points

-1.7 to 1.1

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Acute Urinary Retention20 of 2,596

16 of 2,602

0.2 points

-0.3 to 0.6

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Pharmacologic Treatment for Lower Urinary Tract Symptoms101 of 2,596

87 of 2,602

0.5 points

-0.5 to 1.6

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Peripheral Arterial Revascularization30 of 2,596

33 of 2,602

-0.1 points

-0.7 to 0.5

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Invasive Prostate Surgical Procedures for Benign Prostatic Hyperplasia23 of 2,596

12 of 2,602

0.4 points

-0.0 to 0.9

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Incidence of High-Grade Prostate Cancer5 of 2,596

3 of 2,602

0.1 points

-0.2 to 0.3

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of CV Safety Endpoint: Number and Percentage of Participants With an Event269 of 2,596

264 of 2,602

0.2 points

-1.4 to 1.9

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Biopsy16 of 2,596

14 of 2,602

0.1 points

-0.4 to 0.5

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Venous Thromboembolic Events44 of 2,596

30 of 2,602

0.5 points

-0.1 to 1.2

5,198NCT03518034

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

TDM Cohort vs Historical Cohort: Number of Participants Categorized Based on Dose Escalation173 of 436

852 of 4,758

21.8 points

17.2 to 26.6

5,194NCT04567628

Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes

Invasive Strategy (INV) vs Conservative Strategy: Number of Participants That Experienced Death From Any Cause145 of 2,588

144 of 2,591

0.0 points

-1.2 to 1.3

5,179NCT01471522

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Invasive Strategy (INV) vs Conservative Strategy: Number of Participants That Experienced Death From Cardiovascular Causes or Myocardial Infarction276 of 2,588

314 of 2,591

-1.5 points

-3.2 to 0.3

5,179NCT01471522

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Invasive Strategy (INV) vs Conservative Strategy: Number of Participants That Experienced Myocardial Infarction210 of 2,588

233 of 2,591

-0.9 points

-2.4 to 0.6

5,179NCT01471522

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Invasive Strategy (INV) vs Conservative Strategy: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest318 of 2,588

352 of 2,591

-1.3 points

-3.1 to 0.5

5,179NCT01471522

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Invasive Strategy (INV) vs Conservative Strategy: deaths from any cause145 of 2,588

144 of 2,591

0.0 points

-1.2 to 1.3

5,179NCT01471522

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Invasive Strategy (INV) vs Conservative Strategy: serious adverse events318 of 2,588

352 of 2,591

-1.3 points

-3.1 to 0.5

5,179NCT01471522

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Opt-in vs Opt-out: Enrollment in GAMEPAD Intervention Study39 of 3,909

45 of 1,267

-2.6 points

-3.8 to -1.6

5,176NCT04536038

Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease

Opt-in vs Opt-out: deaths from any cause0 of 3,909

1 of 1,267

-0.1 points

-0.4 to 0.0

5,176NCT04536038

Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=84

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03518034-2e29ac2c",
        "title": "AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of All Cause Mortality",
        "summary": "144 of 2596 against 148 of 2602; risk difference -0.1 points, 95% interval -1.4 to 1.1; NCT03518034, A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men",
        "record": "/library/comparisons/NCT03518034-2e29ac2c",
        "nct_id": "NCT03518034",
        "kind": "outcome",
        "participants": 5198,
        "risk_difference": {
          "value": -0.0014093698221943757,
          "lower": -0.01398992884040385,
          "upper": 0.011166498693297038
        },
        "group_1": "144 of 2,596",
        "group_2": "148 of 2,602",
        "difference": "-0.1 points",
        "interval": "-1.4 to 1.1",
        "trial_title": "A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men"
      },
      {
        "id": "NCT03518034-3af6284d",
        "title": "AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer",
        "summary": "12 of 2596 against 11 of 2602; risk difference 0.0 points, 95% interval -0.3 to 0.4; NCT03518034, A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men",
        "record": "/library/comparisons/NCT03518034-3af6284d",
        "nct_id": "NCT03518034",
        "kind": "outcome",
        "participants": 5198,
        "risk_difference": {
          "value": 0.0003949788535309454,
          "lower": -0.0034746852726501055,
          "upper": 0.004308268577893304
        },
        "group_1": "12 of 2,596",
        "group_2": "11 of 2,602",
        "difference": "0.0 points",
        "interval": "-0.3 to 0.4",
        "trial_title": "A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=85",
  "request_id": "WdaDnQxrWlgCxl4A"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?